Want to see ACET full AI Analyst Report?
Top Page
Adicet Bio
(NASDAQ:ACET)
Select Model
Select Model
Rating:47Neutral
Price Target:
$8.00
▼(-2.68% Downside)
Action:Reiterated
Date:06/19/26
The score is primarily constrained by weak financial performance—no revenue, large ongoing losses, and significant cash burn—partially offset by low leverage on the balance sheet. Technicals are neutral with modest short-term stabilization but a weaker longer-term trend, while valuation is limited by negative earnings and no dividend support; corporate governance continuity provides a small positive.
Positive Factors
Low Leverage
A low debt load gives Adicet durable financial flexibility for a clinical-stage biotech: it reduces near-term default risk and preserves capacity to access debt markets if needed. Low leverage eases interest obligations and supports continued R&D spending without heavy fixed financing costs.
Negative Factors
No Product Revenue
With no revenue, Adicet lacks operating cash inflows to fund development, making it dependent on external financing. This structural absence of product cash generation limits self-sufficiency, increases funding uncertainty, and constrains long-term planning without clinical or commercial milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
A low debt load gives Adicet durable financial flexibility for a clinical-stage biotech: it reduces near-term default risk and preserves capacity to access debt markets if needed. Low leverage eases interest obligations and supports continued R&D spending without heavy fixed financing costs.
Read all positive factors
Adicet Bio (ACET) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$80.77M
Dividend YieldN/A
Average Volume (3M)103.05K
Price to Earnings (P/E)―
Beta (1Y)1.77
Revenue GrowthN/A
EPS Growth27.27%
CountryUS
Employees152
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-14.90
Shares Outstanding9,348,236
10 Day Avg. Volume78,407
30 Day Avg. Volume103,045
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-39.77
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$20.50Price Target Upside149.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-8.34
Revenue Forecast (FY)N/A
Adicet Bio Business Overview & Revenue Model
Company Description
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen rece...
How the Company Makes Money
Adicet Bio does not sell commercial products and, as a clinical-stage biotechnology company, it has historically generated little to no recurring revenue from product sales (null for product sales revenue). When Adicet Bio has revenue, it is prima...
Adicet Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 24.99M | 9.73M |
| Gross Profit | -1.34M | -6.38M | 0.00 | 0.00 | 24.99M | 9.73M |
| EBITDA | -102.73M | -110.39M | -110.65M | -136.53M | -64.70M | -60.41M |
| Net Income | -108.83M | -116.80M | -117.12M | -142.66M | -69.79M | -62.00M |
Balance Sheet | ||||||
| Total Assets | 169.38M | 192.35M | 220.22M | 207.29M | 330.69M | 338.94M |
| Cash, Cash Equivalents and Short-Term Investments | 137.59M | 158.53M | 176.30M | 159.71M | 257.66M | 277.54M |
| Total Debt | 13.90M | 14.74M | 17.23M | 20.92M | 21.02M | 20.94M |
| Total Liabilities | 29.32M | 33.15M | 33.61M | 37.12M | 38.35M | 35.81M |
| Stockholders Equity | 140.06M | 159.21M | 186.61M | 170.18M | 292.34M | 303.13M |
Cash Flow | ||||||
| Free Cash Flow | -91.62M | -96.98M | -93.50M | -98.18M | -61.55M | -64.10M |
| Operating Cash Flow | -91.34M | -95.25M | -92.38M | -93.72M | -44.77M | -51.05M |
| Investing Cash Flow | 24.13M | 2.39M | -119.24M | -4.46M | -16.78M | -2.80M |
| Financing Cash Flow | 75.28M | 75.25M | 111.31M | 236.00K | 41.51M | 242.69M |
Adicet Bio Technical Analysis
Positive
8.22
Price Trends
8.07
Positive
7.57
Positive
9.11
Negative
Market Momentum
0.06
Negative
55.33
Neutral
73.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACET, the sentiment is Positive. The current price of 8.22 is above the 20-day moving average (MA) of 7.95, above the 50-day MA of 8.07, and below the 200-day MA of 9.11, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 55.33 is Neutral, neither overbought nor oversold. The STOCH value of 73.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACET.
Adicet Bio Risk Analysis
Adicet Bio disclosed 24 risk factors in its most recent earnings report. Adicet Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adicet Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $86.59M | -3.47 | -201.43% | ― | ― | 33.86% | |
48 Neutral | $550.14M | -0.11 | 275.30% | ― | 49.94% | 44.76% | |
48 Neutral | $239.75M | -2.75 | -73.16% | ― | ― | -18.99% | |
47 Neutral | $80.77M | -0.58 | -80.35% | ― | ― | 27.27% | |
45 Neutral | $71.46M | -0.89 | -68.98% | ― | ― | -26.14% |
* Healthcare Sector Average
ACET
Adicet Bio
8.64
-1.14
-11.63%
STRO
Sutro Biopharma
33.20
26.40
388.24%
PMVP
PMV Pharmaceuticals
1.34
0.29
27.62%
GANX
Gain Therapeutics
2.03
0.46
29.30%
IMMX
Immix Biopharma
10.31
8.12
370.78%
ARTV
Artiva Biotherapeutics, Inc.
9.70
8.17
533.99%
Adicet Bio Corporate Events
Executive/Board ChangesShareholder Meetings
Adicet Bio Stockholders Back Directors, Pay and Auditor
Positive
Jun 18, 2026
On June 17, 2026, Adicet Bio, Inc. held its 2026 Annual Meeting of Stockholders, where investors elected Jeffrey Chodakewitz, Steve Dubin and Michael Grissinger as Class II directors to serve three-year terms ending with the 2029 annual meeting. T...
Private Placements and Financing
Adicet Bio Issues Pre-Funded Warrant in Equity Exchange
Neutral
Apr 28, 2026
On April 27, 2026, Adicet Bio, Inc. entered into an exchange agreement with RA Capital Management, L.P. and RA Capital Healthcare Fund, L.P. under which RA Capital exchanged 250,000 shares of Adicet’s common stock for a pre-funded warrant to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.